| n (%) |
Male gender | 55 (52.4) |
Age, y* | 62.3 ± 12.0 |
Employed fulltime or part-time | 38 (36.2) |
Education |
|
≤12 years | 70 (66.7) |
Living with family or other adults | 99 (94.3) |
Cancer type |
|
Breast cancer | 35 (33.3) |
Colorectal cancer | 30 (28.6) |
Hepatocellular carcinoma | 31 (29.5) |
Renal cell carcinoma | 9 (8.6) |
ECOG performance status |
|
0 | 81 (77.1) |
1 | 23 (21.9) |
2 | 1 (1.0) |
Anti-cancer agents |
|
Capecitabine | 65 (61.9) |
Sorafenib | 31 (29.5) |
Sunitinib | 9 (8.6) |
Time since start of treatment with relevant drug, month* | 4.6 ± 5.7 |
CTCAE grade of HFS |
|
Grade 1 | 67 (63.8) |
Grade 2 | 36 (34.3) |
Grade 3 | 2 (1.9) |